Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Post by Jefferam1on Dec 04, 2017 3:32pm
179 Views
Post# 27087506

How big can this get?

How big can this get?Best case scenario, what are we looking at?
They have roughly 250M shares fully diluted.
How big can this Market cap get in the next 3-5 years?
Are we best in a royality deal? A take over? 
If we hit 1$ share that would be Market cap of 250M, Yeah thats totally possible if drug proven to work.
What about 10$, Market cap of 2.5B? how possible is that?
If the three main drugs has a roughly 24B in sales annually and we are able to tap in 10% of that market and make a 10% royalty, that's 240M profit annually, what would that put us at? Are these numbers even possible? Anyone with bigger pharma experience, I'm curious to hear what you think this could turn out to be?

Obvioulsy 1$ is very possible (and probably within next 12 months)., Trying to figure out if 5 or 10 is also possible?
Thoughts?

Bullboard Posts